BTC $79,153.88 -0.74%
ETH $2,493.04 +0.04%
BNB $740.52 -0.97%
XRP $1.40 -0.92%
SOL $104.02 -2.00%
TRX $0.3337 -0.42%
DOGE $0.0903 +1.31%
ADA $0.2213 +1.38%
BCH $260.88 +1.76%
LINK $12.94 +5.18%
HYPE $85.20 -3.24%
AAVE $132.50 -0.50%
SUI $0.8189 +2.82%
XLM $0.1915 +4.06%
ZEC $1,170.07 -4.41%
BTC $79,153.88 -0.74%
ETH $2,493.04 +0.04%
BNB $740.52 -0.97%
XRP $1.40 -0.92%
SOL $104.02 -2.00%
TRX $0.3337 -0.42%
DOGE $0.0903 +1.31%
ADA $0.2213 +1.38%
BCH $260.88 +1.76%
LINK $12.94 +5.18%
HYPE $85.20 -3.24%
AAVE $132.50 -0.50%
SUI $0.8189 +2.82%
XLM $0.1915 +4.06%
ZEC $1,170.07 -4.41%

Sonnet Biotherapeutics has received shareholder approval to merge with Hyperliquid Strategies Inc

2025-12-02 22:26:45

According to market news, Nasdaq-listed biotech company Sonnet Biotherapeutics has received shareholder approval to merge with Hyperliquid Strategies Inc.

Previously, it was reported that Hyperliquid Strategies submitted an S-1 filing to raise up to $1 billion, which may be used to purchase HYPE tokens.

app_icon
ChainCatcher Building the Web3 world with innovations.